Nivolumab was FDA approved on the 22nd of December 2014 after proving effective for the treatment of patients with unresectable or metastatic melanoma who no longer responded to ipilimumab and B-Raf proto-oncogene (BRAF) inhibitors [58]. This evidence concerns the gene BRAF and metastatic melanoma.